Literature DB >> 19442140

Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance.

Rosaria Gangemi1, Laura Paleari, Anna Maria Orengo, Alfredo Cesario, Leonardo Chessa, Silvano Ferrini, Patrizia Russo.   

Abstract

Normal somatic stem cells (SC) are naturally resistant to chemotherapeutic agents due to their expression of various membrane transporter molecules (such as MDR-1), detoxifying enzymes and DNA repair proteins. In addition, they also have a slow rate of cell turnover and therefore escape from chemotherapeutic agents that target rapidly replicating cells. Cancer stem cells (CSC), being the mutated counterparts of normal SC, also have similar properties, which allow them to survive therapy. These surviving CSC then repopulate the tumor, causing relapse. The purpose of this review is to understand the most current research into the cellular and molecular biology of CSC. Topics that will be explored are the origin of CSC, the CSC niche, the regulation of self-renewal in normal and cancer SC, and CSC as therapeutic targets.

Entities:  

Mesh:

Year:  2009        PMID: 19442140     DOI: 10.2174/092986709788186147

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  58 in total

1.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

Review 2.  Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.

Authors:  Suoyuan Li; Wei Sun; Hongsheng Wang; Dongqing Zuo; Yingqi Hua; Zhengdong Cai
Journal:  Tumour Biol       Date:  2015-02-11

Review 3.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

4.  Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.

Authors:  Masaya Kai; Noriko Kanaya; Shang V Wu; Carlos Mendez; Duc Nguyen; Thehang Luu; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2015-04-23       Impact factor: 4.872

5.  Synthesis and characterization of DNA minor groove binding alkylating agents.

Authors:  Prema Iyer; Ajay Srinivasan; Sreelekha K Singh; Gerard P Mascara; Sevara Zayitova; Brian Sidone; Elise Fouquerel; David Svilar; Robert W Sobol; Michael S Bobola; John R Silber; Barry Gold
Journal:  Chem Res Toxicol       Date:  2012-12-26       Impact factor: 3.739

6.  Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry: a valuable tool for diagnosis and prognosis evaluation.

Authors:  Ningfang Wang; Lan Shi; Huiyu Li; Yanjie Hu; Wen Du; Wei Liu; Jin'e Zheng; Shiang Huang; Xincai Qu
Journal:  Tumour Biol       Date:  2012-01-13

Review 7.  Metabolism and epigenetics of pancreatic cancer stem cells.

Authors:  M Perusina Lanfranca; J K Thompson; F Bednar; C Halbrook; C Lyssiotis; B Levi; T L Frankel
Journal:  Semin Cancer Biol       Date:  2018-09-28       Impact factor: 15.707

8.  Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells.

Authors:  Jagrut Patel; Somesh Baranwal; Ian M Love; Nirmita J Patel; Steven R Grossman; Bhaumik B Patel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.

Authors:  Caterina Fanali; Donatella Lucchetti; Marisa Farina; Maddalena Corbi; Valerio Cufino; Achille Cittadini; Alessandro Sgambato
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 10.  Mechanisms of resistance to pemetrexed in non-small cell lung cancer.

Authors:  Jiaqi Liang; Tao Lu; Zhencong Chen; Cheng Zhan; Qun Wang
Journal:  Transl Lung Cancer Res       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.